Metabolomics and Proteomics in Type 2 Diabetes

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2020 May 22

PMID 32437301

Citations 67

Authors

Zsu-Zsu Chen

Robert E Gerszten

Affiliations

Soon will be listed here.

Abstract

The persistent increase in the worldwide burden of type 2 diabetes mellitus (T2D) and the accompanying rise of its complications, including cardiovascular disease, necessitates our understanding of the metabolic disturbances that cause diabetes mellitus. Metabolomics and proteomics, facilitated by recent advances in high-throughput technologies, have given us unprecedented insight into circulating biomarkers of T2D even over a decade before overt disease. These markers may be effective tools for diabetes mellitus screening, diagnosis, and prognosis. As participants of metabolic pathways, metabolite and protein markers may also highlight pathways involved in T2D development. The integration of metabolomics and proteomics with genomics in multiomics strategies provides an analytical method that can begin to decipher causal associations. These methods are not without their limitations; however, with careful study design and sample handling, these methods represent powerful scientific tools that can be leveraged for the study of T2D. In this article, we aim to give a timely overview of circulating metabolomics and proteomics findings with T2D observed in large human population studies to provide the reader with a snapshot into these emerging fields of research.

Citing Articles

Energy metabolism in health and diseases.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K Signal Transduct Target Ther. 2025; 10(1):69.

PMID: 39966374 PMC: 11836267. DOI: 10.1038/s41392-025-02141-x.

Untargeted metabolomics analysis of glycerophospholipid metabolism in very low birth weight infants administered multiple oil lipid emulsions.

Zeng X, Yu T, Xia L, Ruan Z BMC Pediatr. 2024; 24(1):849.

PMID: 39736612 PMC: 11686898. DOI: 10.1186/s12887-024-05343-4.

Novel type 2 diabetes prediction score based on traditional risk factors and circulating metabolites: model derivation and validation in two large cohort studies.

Xie R, Herder C, Sha S, Peng L, Brenner H, Schottker B EClinicalMedicine. 2024; 79:102971.

PMID: 39720612 PMC: 11667638. DOI: 10.1016/j.eclinm.2024.102971.

Changes in the gut microbiota and derived fecal metabolites may play a role in tacrolimus-induced diabetes in mice.

Qian M, Jiang Z, Xu C, Wang L, Hu N Future Microbiol. 2024; 20(3):237-246.

PMID: 39711145 PMC: 11812427. DOI: 10.1080/17460913.2024.2444761.

Microbial and proteomic signatures of type 2 diabetes in an Arab population.

Murugesan S, Yousif G, Djekidel M, Gentilcore G, Grivel J, Al Khodor S J Transl Med. 2024; 22(1):1132.

PMID: 39707404 PMC: 11662572. DOI: 10.1186/s12967-024-05928-8.

References

Randle P, Garland P, Hales C, Newsholme E . The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1(7285):785-9. DOI: 10.1016/s0140-6736(63)91500-9. View

Gieger C, Geistlinger L, Altmaier E, de Angelis M, Kronenberg F, Meitinger T . Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008; 4(11):e1000282. PMC: 2581785. DOI: 10.1371/journal.pgen.1000282. View

Wang T, Ngo D, Psychogios N, Dejam A, Larson M, Vasan R . 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013; 123(10):4309-17. PMC: 3784523. DOI: 10.1172/JCI64801. View

Bales J, Higham D, Howe I, Nicholson J, Sadler P . Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin Chem. 1984; 30(3):426-32. View

Ference B, Robinson J, Brook R, Catapano A, Chapman M, Neff D . Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016; 375(22):2144-2153. DOI: 10.1056/NEJMoa1604304. View

Salamanca-Cardona L, Shah H, Poot A, Correa F, Di Gialleonardo V, Lui H . In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors. Cell Metab. 2017; 26(6):830-841.e3. PMC: 5718944. DOI: 10.1016/j.cmet.2017.10.001. View

Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

Lynch C, Adams S . Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014; 10(12):723-36. PMC: 4424797. DOI: 10.1038/nrendo.2014.171. View

Stancakova A, Civelek M, Saleem N, Soininen P, Kangas A, Cederberg H . Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes. 2012; 61(7):1895-902. PMC: 3379649. DOI: 10.2337/db11-1378. View

10.

Tremblay F, Marette A . Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001; 276(41):38052-60. DOI: 10.1074/jbc.M106703200. View

11.

Drogan D, Dunn W, Lin W, Buijsse B, Schulze M, Langenberg C . Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study. Clin Chem. 2014; 61(3):487-97. DOI: 10.1373/clinchem.2014.228965. View

12.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

13.

Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson A, Miftaraj M . Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017; 376(15):1407-1418. DOI: 10.1056/NEJMoa1608664. View

14.

Meister A, Tate S . Glutathione and related gamma-glutamyl compounds: biosynthesis and utilization. Annu Rev Biochem. 1976; 45:559-604. DOI: 10.1146/annurev.bi.45.070176.003015. View

15.

Yan-Do R, MacDonald P . Impaired "Glycine"-mia in Type 2 Diabetes and Potential Mechanisms Contributing to Glucose Homeostasis. Endocrinology. 2017; 158(5):1064-1073. DOI: 10.1210/en.2017-00148. View

16.

Robbins J, Herzig M, Morningstar J, Sarzynski M, Cruz D, Wang T . Association of Dimethylguanidino Valeric Acid With Partial Resistance to Metabolic Health Benefits of Regular Exercise. JAMA Cardiol. 2019; 4(7):636-643. PMC: 6551586. DOI: 10.1001/jamacardio.2019.1573. View

17.

Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C . A genome-wide perspective of genetic variation in human metabolism. Nat Genet. 2009; 42(2):137-41. PMC: 3773904. DOI: 10.1038/ng.507. View

18.

Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J . Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9. DOI: 10.1056/NEJMoa1500858. View

19.

Kollerits B, Lamina C, Huth C, Marques-Vidal P, Kiechl S, Seppala I . Plasma Concentrations of Afamin Are Associated With Prevalent and Incident Type 2 Diabetes: A Pooled Analysis in More Than 20,000 Individuals. Diabetes Care. 2017; 40(10):1386-1393. DOI: 10.2337/dc17-0201. View

20.

Donnelly L, Doney A, Hattersley A, Morris A, Pearson E . The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med. 2006; 23(2):128-33. DOI: 10.1111/j.1464-5491.2005.01755.x. View